

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bendamustine hydrochloride

INITIATION – treatment naive CLL

Prerequisites (tick boxes where appropriate)

- The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment
- and The patient is chemotherapy treatment naive
- and The patient is unable to tolerate toxicity of full-dose FCR
- and Patient has ECOG performance status 0-2
- and Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6
- and Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

INITIATION – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- The patient has indolent low grade NHL requiring treatment
- and Patient has a WHO performance status of 0-2
- and
 - Patient is treatment naive
 - and Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+)
- or
 - Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen
 - and Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles
- or
 - The patient has not received prior bendamustine therapy
 - and Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)
 - and Patient has had a rituximab treatment-free interval of 12 months or more
- or Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Bendamustine hydrochloride - continued

CONTINUATION – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine
and
 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles

or

- Patients have not received a bendamustine regimen within the last 12 months
and

- Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)
and
 Patient has had a rituximab treatment-free interval of 12 months or more

or

- Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients

Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.

INITIATION – Hodgkin's lymphoma*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has Hodgkin's lymphoma requiring treatment
and
 Patient has a ECOG performance status of 0-2
and
 Patient has received one prior line of chemotherapy
and
 Patient's disease relapsed or was refractory following prior chemotherapy
and
 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m² twice per cycle, for a maximum of four cycles

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date: